71results about How to "High clinical value" patented technology

The invention relates to the field of cell therapy. Specifically, the invention relates to a method for producing a mesenchymal stem cell population, a mesenchymal stem cell population produced by themethod and a culture supernatant thereof, and a pharmaceutical composition comprising such cells or a culture supernatant thereof. The invention also relates to the mesenchymal stem cell population and a culture supernatant thereof, and uses of the mesenchymal stem cell population and the culture supernatant in prevention and treatment of diseases.

The invention relates to a hepatitis B surface antigen (HBsAg) resistant antibody (in particular to a humanized antibody), nucleic acid molecules for coding the antibody, a method for preparing the antibody and a pharmaceutical composition containing the antibody. In addition, the invention relates to application of the antibody and the pharmaceutical composition. The antibody and the pharmaceutical composition can be used for preventing and / or treating HBV infection and diseases (such as hepatitis B) related to the HBV infection, used for neutralizing the HBV virulence in the body of a subject (such as a person), or used for reducing the HBV DNA and / or HBsAg serum level in the body of the subject.

The invention relates to the medical biology field, in particular to an anti-BCMA (B-cell maturation antigen) antibody, an antigen binding fragment thereof, and a chimeric antigen receptor (CAR) containing the anti-BCMA antibody. The invention also relates to a nucleic acid molecule capable of encoding the CAR, a modified immune cell containing the CAR, and a method for preparing the modified immune cell. The invention also relates to the purposes of the CARs and the modified immune cell for preventing and / or treating B-cell related illness states (such as B-cell related and plasma cell related malignant tumors and autoimmune diseases) and a method for preventing and / or treating the B-cell related illness states.

The invention belongs to the technical field of bio-medicine, and in particular relates to an orlistat nano-microsphere as well as a preparation method and an application thereof in anti-tumor drugs. The orlistat nano-microsphere provided by the invention is prepared by mixing orlistat and a drug-carrying material, wherein the drug-carrying material is polyethylene glycol-polycaprolactone (mPEG-PCL); the mass ratio of the orlistat to the mPEG-PCL is at (1-2) to (3-10); and the molecular weight ratio of mPEG to PCL is at 2000 to 10000 or 2000 to 20000. The polymer nano-microsphere provided by the invention is prepared by loading the orlistat on the nano-material, so that a hydrophobic property of the nano-microsphere is changed; and through the sustained-release property of the microsphere, the microsphere can be used for preparing drugs for resisting tumor diseases; therefore, the nano-microsphere is huge in potential clinical value.

The invention relates to the field of virus and the field of tumor treatment. Concretely, the invention relates to enterovirus type 68 (EV-D68) or a modified form thereof, or a genomic sequence or cDNA sequence comprising the EV-D68 or the modified form of the EV-D68, or nucleic acid molecules of a complementary sequences of the genomic sequence or cDNA sequence, applications in treating tumors for a subject such as a human being, and applications in preparing pharmaceutical compositions for treating the tumors for the subject such as a human being. The invention also relates to a method for treating the tumors. The method includes steps of applying the EV-D68 or the modified form of the EV-D68, or the genomic sequence or cDNA sequence comprising the EV-D68 or the modified form of the EV-D68 or the nucleic acid molecules of the complementary sequences of the genomic sequence or cDNA sequence to the subject who needs the treatment.

The invention provides a medical intelligent mattress sleep monitoring device and method based on a piezoelectric ceramic sensor. The medical intelligent mattress sleep monitoring device includes a piezoelectric ceramic sensor unit, a signal amplification and filtering unit, a microprocessor unit, a communication unit, a USB power supply unit and the like, and is characterized in that the piezoelectric ceramic sensor unit places piezoelectric ceramic sensors. The unit is composed of plurality of sensors. The sensor unit is connected to the signal amplification filter unit through wires. The signal amplification and filtering unit completes the amplification and filtering of original vital sign signals, and the original vital sign signals are sent to the microprocessor unit after being amplified and filtered. The microprocessor unit completes data analysis and processing of the amplified and filtered signals, and finally vital sign signals such as on-bed respiration, heart rate and bodymovement are obtained. According to the medical intelligent mattress sleep monitoring device and method, the monitoring of physiological states such as on-bed heart rate, respiration, body movement is realized by sensing the subtle pressure change of a human body. The medical intelligent mattress sleep monitoring device and method have the characteristics of high accuracy, low cost and the like,are suitable for ordinary consumers, and have a certain market prospect and promotion value.

The invention relates to the field of viruses and the field of tumor treatment, in particular to a pseudorabies virus (PRV) or a modification form thereof, or a genome sequence or cDNA sequence with the PRV and the modification form of the PRV, or a nucleic acid molecule with a compensatory sequence of the cDNA sequence, application of the nucleic acid molecule to treating tumors and / or reducing or restraining tumor relapse in a testee (such as human), and application to preparing a pharmaceutical composition for treating the tumors and / or reducing or restraining the tumor relapse in the testee (such as human). The invention further relates to a method for treating the tumors and / or reducing or restraining the tumor relapse. The method includes the step of applying the PRV or the modification form of the PRV to the testee needing the PRV or the modification form of the PRV or the nucleic acid molecule with the genome sequence of the PRV or the modification form of the PRV.

The invention relates to the field of viruses and the field of tumor treatment, in particular to to coxsackievirus B3 (CVB3) and a modification form thereof, a genomic sequence or a cDNA sequence containing the CVB3 or the modification form of the CVB3, or a nucleic acid molecule with a complementary sequence of the genomic sequence or the cDNA sequence, application to treat a tumor of a subject (for example, a human), and application to prepare a pharmaceutical composition for treating the tumor of the subject (such as the human). The invention further relates to a method for treating the tumor, and the method comprises the step that the CVB3 or the modification form of the CVB3, or the genomic sequence or the cDNA sequence containing the CVB3 or the modification form of the CVB3, or thenucleic acid molecular of the complementary sequence of the genomic sequence or the cDNA sequence are applied to the subject needing tumor treating.

The invention relates to the field of viruses and the field of tumor therapy, in particular to coxsackie B virus 1 (CVB1) or a modified form thereof, or a nucleic acid molecule comprising a genomic sequence or a cDNA sequence comprising the CVB1 or the modified form thereof or comprising complementary sequences of the genomic sequence or the cDNA sequence, use for treatment of tumors in a subject(such as a person), and use for the preparation of a pharmaceutical composition for treatment of the tumors in the subject (such as a person). The invention further relates to a method for treatment of the tumors. The method comprises the step of applying the CVB1 or the modified form thereof, or the nucleic acid molecule comprising the genomic sequence or the cDNA sequence comprising the CVB1 orthe modified form thereof or comprising the complementary sequences of the genomic sequence or the cDNA sequence to the subject in need.

The invention provides an anticancer intermediate based on PKI-587 and a polyethylene glycol coupled anticancer drug, and preparation methods and application thereof, belonging to the field of treatment of cancers. The anticancer intermediate has a general structural formula as described in the specification, and at least one AC in the general structural formula is the anticancer drug PKI-587. Thepolyethylene glycol coupled anticancer drug has a general structural formula as described in the specification. The above two drugs can realize combined medication of the targeting anticancer drug PKI-587 and a plurality of other anticancer drugs, so toxic response caused by mutual influence and pharmacokinetics of a plurality of other anticancer drugs can be prevented during individual administration of the anticancer drugs, multidrug resistance of cancers is overcome, and synergistic effect is exerted; and the two drugs can be used for preparing anticancer drugs with targeting effect and have critical clinical value and wide market prospects.

The invention belongs to the technical field of medicines, particularly relates to fibric acid compounds, pharmaceutically acceptable salts or esters, stereoisomers, prodrugs, hydrates, solvates, crystalline forms, metabolite forms, or any combinations or mixtures thereof, a pharmaceutical composition containing the compound, the pharmaceutically acceptable salt or ester, the stereoisomer, the prodrug, the hydrate, the solvate, the crystal form, the metabolite form or any combination or mixture, and medical uses of the compounds, the pharmaceutically acceptable salts or esters, the stereoisomers, the prodrugs, the hydrates, the solvates, the crystal forms, the metabolite forms or any combinations or mixtures thereof. For example, the compounds of the present invention can be used for preventing and / or treating metabolic diseases (such as metabolic syndrome, non-alcoholic fatty liver disease, and / or diabetes).

The invention discloses a method for screening Down's syndrome through second trimester maternal serum alpha-fetoprotein variants L2 and L3. The method comprises the following steps of collecting a plurality of pregnant women who are definitely diagnosed as DS fetuses through amniotic fluid cell chromosome karyotyping for forming a case set, and randomly selecting a plurality of pregnant women with normal fetus development for forming a comparing set; testing the AFP-L2 and AFP-L3 levels of the serum of the two sets of pregnant women according to an enzyme linked immunosorbent assay method, calculating an optimal critical value and a curve lower area of the AFP-L2 and AFP-L3 screened DS fetus according to an ROC curve; and in testing, and when the AFP-L2 and AFP-L3 levels of the serum of the to-be-tested pregnant woman exceed the preset threshold, determining a fact that the fetus of the to-be-tested pregnant woman is the DS fetus. The method has a beneficial effect that the second trimester maternal serum alpha-fetoprotein variants L2 and L3 realize relatively high sensitivity and specificity in screening the DS fetus and are relatively good markers for screening the DS.

The invention relates to the field of disease treatment and immunology, in particular to an anti-PD-1 antibody or an antigen-binding fragment thereof, a nucleic acid molecule for encoding the anti-PD-1 antibody or the antigen-binding fragment thereof, a method for preparing the anti-PD-1 antibody or the antigen-binding fragment thereof, and a pharmaceutical composition containing the anti-PD-1 antibody or the antigen-binding fragment thereof. The invention further relates to an application of the above antibody ( especially the humanized antibody) or the antigen-binding fragment thereof in preparation of a medicine, wherein the medicine is used for improving immune cell activity and enhancing immune response or is used for preventing and / or treating tumors or infections.